Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Song Cheol Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4552-4169; OpenAlex author ID A5066037517. Sources: ClinicalTrials.gov.

Their work

Papers
108 (first author 12, last author 43)
Trials
4 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
256
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 3 papers · 2015: 1 paper · 2016: 8 papers, 1 trial · 2017: 10 papers, 1 trial · 2018: 9 papers, 1 trial · 2019: 10 papers · 2020: 11 papers · 2021: 13 papers · 2022: 12 papers · 2023: 8 papers, 1 trial · 2024: 8 papers · 2025: 6 papers · 2026: 5 papers

Papers 50 of 108

  1. An Exosomal Signature for Preoperative Detection of Occult Liver Metastasis in Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.3840↗
  2. Minimally invasive vs. open-extended distal pancreatectomy with multi-organ resection: postoperative and oncological outcomes for left-sided pancreatic ductal … Last author DOI 10.1007/s00464-025-12452-3↗
  3. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  4. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  5. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  6. Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natural killer cells in pancreatic cancer. Last author DOI 10.1016/j.biopha.2025.118714↗
  7. Applicability of current nodal staging system for resected pancreatic cancer after neoadjuvant therapy: a retrospective study. Last author DOI 10.1016/j.hpb.2025.04.011↗
  8. Oncological outcomes of palliative minimally invasive distal pancreatectomy for unexpected metastatic pancreatic ductal adenocarcinoma: A single-center experie… Last author DOI 10.1016/j.surg.2025.109331↗
  9. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Last author DOI 10.1245/s10434-024-16437-9↗
  10. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Last author DOI 10.1245/s10434-024-16618-6↗
  11. Retraction: Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced … Co-author DOI 10.18632/oncotarget.28813↗
  12. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Last author DOI 10.1007/s00261-024-04299-4↗
  13. Reply to: "Revolutionizing pancreatic cancer management: AI-enhanced vascular burden index assessment with CT imaging". First author DOI 10.1016/j.ejso.2024.108576↗
  14. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  15. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.09.050↗
  16. Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. Last author DOI 10.1097/js9.0000000000001389↗
  17. Prognostic model for resected borderline and locally advanced pancreatic cancer after neoadjuvant chemotherapy. Last author DOI 10.1097/js9.0000000000001927↗
  18. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 1… Co-author DOI 10.3348/kjr.2023.1235↗
  19. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Last author DOI 10.4143/crt.2023.977↗
  20. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jhbp.1272↗
  21. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  22. Multi-biomarker panel prediction model for diagnosis of pancreatic cancer. Co-author DOI 10.1002/jhbp.986↗
  23. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. Co-author DOI 10.1007/s00330-023-09584-2↗
  24. Robotic versus laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: A propensity score-matched analysis. Last author DOI 10.1016/j.hbpd.2022.06.001↗
  25. Outcomes of Distal Pancreatectomy With Celiac Axis Resection for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002218↗
  26. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Last author DOI 10.4143/crt.2022.409↗
  27. Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
  28. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Last author DOI 10.1002/jhbp.1192↗
  29. The impact of preoperative EUS-FNA for distal resectable pancreatic cancer: Is it really effective enough to take risks? Co-author DOI 10.1007/s00464-021-08627-3↗
  30. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… Co-author DOI 10.1016/j.hpb.2022.01.012↗
  31. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Last author DOI 10.1016/j.ijsu.2022.106851↗
  32. Direct cell-to-cell transfer in stressed tumor microenvironment aggravates tumorigenic or metastatic potential in pancreatic cancer. Co-author DOI 10.1038/s41525-022-00333-w↗
  33. Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Co-author DOI 10.1073/pnas.2119048119↗
  34. A Serum Marker for Early Pancreatic Cancer With a Possible Link to Diabetes. Co-author DOI 10.1093/jnci/djab191↗
  35. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003945↗
  36. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  37. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Last author DOI 10.1177/17588359221097190↗
  38. Predictive Performance of Current Nodal Staging Systems in Various Categories of Pancreatic Cancer. Last author DOI 10.1245/s10434-021-10641-7↗
  39. Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfron… Last author DOI 10.21037/gs-22-304↗
  40. A comparison of minimally invasive vs open distal pancreatectomy for resectable pancreatic ductal adenocarcinoma: Propensity score matching analysis. Last author DOI 10.1002/jhbp.853↗
  41. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. Last author DOI 10.1007/s00330-020-07134-8↗
  42. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  43. Imaging Strategy that Achieves Ultrahigh Contrast by Utilizing Differential Esterase Activity in Organs: Application in Early Detection of Pancreatic Cancer. Co-author DOI 10.1021/acsnano.1c05165↗
  44. Pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor. Co-author DOI 10.1038/s12276-021-00582-2↗
  45. Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. Last author DOI 10.1093/bjs/znab229↗
  46. Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadren… Last author DOI 10.3390/biomedicines9101291↗
  47. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker… Last author DOI 10.3390/biomedicines9111599↗
  48. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Last author DOI 10.3390/biomedicines9111706↗
  49. Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm10245784↗
  50. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Co-author DOI 10.4174/astr.2021.100.3.144↗

Trials 4

  1. Modified Frailty Index for Minimally Invasive Distal Pancreatectomy Principal investigator NCT05837793↗
  2. Effect of Thrombin-containing Collagen-based Hemostatic Matrix Study chair NCT04357483↗
  3. Clinical Outcomes of Surgery After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Principal investigator NCT05888129↗
  4. Evaluation of Killing Activity of Expanded Natural Killer Cells From Blood in Patients With Pancreatic Cancer Principal investigator NCT03665571↗

Closest collaborators

The 25 strongest of 256 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dae Wook Hwang · 54 shared papers, 2014–2026 · strength 7.03
  2. Ki Byung Song · 53 shared papers, 2013–2026 · strength 6.42
  3. Woohyung Lee · 30 shared papers, 2020–2026 · strength 4.85
  4. Eunsung Jun · 33 shared papers, 2016–2026 · strength 4.48
  5. Yejong Park · 24 shared papers, 2020–2026 · strength 3.78
  6. Kyu‐pyo Kim · 27 shared papers, 2014–2026 · strength 3.26
  7. Changhoon Yoo · 24 shared papers, 2017–2026 · strength 3.12
  8. Seung‐Mo Hong · 22 shared papers, 2013–2025 · strength 2.23
  9. Seung Soo Lee · 13 shared papers, 2018–2026 · strength 2.09
  10. Baek‐Yeol Ryoo · 18 shared papers, 2017–2026 · strength 2.08
  11. Jae Ho Byun · 11 shared papers, 2018–2025 · strength 1.67
  12. Hyoung Jung Kim · 11 shared papers, 2017–2025 · strength 1.66
  13. Jaewoo Kwon · 13 shared papers, 2019–2023 · strength 1.56
  14. Jin Hee Kim · 10 shared papers, 2018–2025 · strength 1.53
  15. Tae Jun Song · 13 shared papers, 2017–2026 · strength 1.47
  16. Bong Jun Kwak · 10 shared papers, 2014–2024 · strength 1.44
  17. Min Kyu Sung · 7 shared papers, 2021–2025 · strength 1.31
  18. Sang Soo Lee · 15 shared papers, 2012–2024 · strength 1.28
  19. Jin‐hong Park · 13 shared papers, 2012–2026 · strength 1.24
  20. Dong Wan Seo · 12 shared papers, 2012–2025 · strength 1.24
  21. Sarang Hong · 10 shared papers, 2019–2023 · strength 1.22
  22. Do Hyun Park · 12 shared papers, 2012–2024 · strength 1.17
  23. Ajay Goel · 6 shared papers, 2022–2026 · strength 1.12
  24. Daniel D. Von Hoff · 6 shared papers, 2022–2026 · strength 1.12
  25. Joon Oh Park · 8 shared papers, 2018–2026 · strength 0.97

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.